Literature DB >> 8430863

Action of C-type natriuretic peptide in isolated canine arteries and veins.

C M Wei1, L L Aarhus, V M Miller, J C Burnett.   

Abstract

C-type natriuretic peptide (CNP) is a hormone that shares structural homology to atrial natriuretic peptide (ANP); however, distinct receptors have been found for each in cultured aortic endothelial and smooth muscle cells. CNP in vivo reduces arterial pressure, atrial pressures, and cardiac output. These actions are consistent with a decrease in cardiac preload. Therefore, the current studies were designed to test the hypothesis that CNP is a vasodilator distinct from ANP. Rings of canine renal and saphenous arteries and renal, saphenous, and femoral veins with and without endothelium were suspended to measure isometric force in an organ chamber. CNP caused significant concentration-dependent relaxations in veins with and without endothelium contracted with phenylephrine (10(-6) log M). In marked contrast, ANP caused no significant relaxation in veins either with or without endothelium. In arterial rings, responses to the peptides were heterogeneous. ANP caused relaxation in renal but not saphenous arteries. CNP induced modest and comparable relaxation in rings of saphenous but not renal arteries with and without endothelium. These results demonstrate that: 1) CNP and not ANP is a relaxing factor of isolated peripheral canine veins, and 2) the responses of arteries to ANP and CNP are heterogeneous. These findings support a distinct biological role for CNP in the regulation of cardiovascular tone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430863     DOI: 10.1152/ajpheart.1993.264.1.H71

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  26 in total

1.  Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.

Authors:  Deborah M Dickey; Kathryn A Barbieri; Christopher M McGuirk; Lincoln R Potter
Journal:  Mol Pharmacol       Date:  2010-06-08       Impact factor: 4.436

Review 2.  Natriuretic peptides in cardiometabolic regulation and disease.

Authors:  Nora E Zois; Emil D Bartels; Ingrid Hunter; Birgitte S Kousholt; Lisbeth H Olsen; Jens P Goetze
Journal:  Nat Rev Cardiol       Date:  2014-05-13       Impact factor: 32.419

Review 3.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

4.  Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide.

Authors:  C M Wei; C H Kim; V M Miller; J C Burnett
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

5.  Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

Authors:  Thomas H Langenickel; Jens Buttgereit; Ines Pagel-Langenickel; Maren Lindner; Jan Monti; Knut Beuerlein; Nidal Al-Saadi; Ralph Plehm; Elena Popova; Jens Tank; Rainer Dietz; Roland Willenbrock; Michael Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

6.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

Authors:  Ondrej Lisy; Brenda K Huntley; Daniel J McCormick; Paul A Kurlansky; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

Review 7.  B-type natriuretic peptide: beyond a diagnostic.

Authors:  Fernando L Martin; Horng H Chen; Alessandro Cataliotti; John C Burnett
Journal:  Heart Fail Clin       Date:  2008-10       Impact factor: 3.179

8.  Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs.

Authors:  P Beaulieu; R Cardinal; A De Léan; C Lambert
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 9.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009

10.  Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.

Authors:  Candace Y W Lee; Horng H Chen; Ondrej Lisy; Suzanne Swan; Courtney Cannon; Hsiao D Lieu; John C Burnett
Journal:  J Clin Pharmacol       Date:  2009-04-24       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.